Cytotoxic immunosuppressive drug treatment has been given to patients with rheumatoid arthritis (RA) and other connective tissue diseases (CTD) who have proved refractory to conventional second line agents, such as gold salts, D-penicillamine, and antimalarial drugs. They are used either continuously or in pulses, but intermittent use of both cytotoxic drugs and corticosteroids, as for lymphoma, has not been reported in rheumatic diseases uncomplicated by vasculitis.
We present a patient with IgA deficiency and classical RA mg/M2, days 1 and 8; procarbazine 1(0 mg/M2, days 1 to 7; prednisolone 40 mg/mi2, days 1 to 14 (body surface area 1-63 m2). Owing to myelosuppression, cyclophosphamide 1 g, day 1, was substituted for nitrogen mustard after the first course. She received four-weekly cycles for six months after which she was in remission, and has remained so when most recently reviewed almost five years later.
The RA also went into complete remission, but three years later she represented with a flare of polyarthritis. Investigations were again consistent with RA (Table 1) . She has to date refused specific antirheumatic treatment and has had progressive severe rheumatoid arthritis.
Discussion
This woman with IgA deficiency would appear to have progressed from classic RA, to RA with SS, and then to DM and SLE, at which time she was rheumatoid factor negative. She then developed Hodgkin's disease, which would seem to have been cured, but after three years in remission RA recurred without evidence of other CTD.
IgA deficiency is well described in association with RA and CTD' and may represent a background immunological predisposition to our patient developing RA with multiple overlap CTD syndromes. Similarly, Hodgkin's disease and nonHodgkin's lymphomas have been described with both IgA deficiency' as well as RA2 and other CTD. 3 The presence of both malignancy and autoimmune disease in a patient with IgA deficiency is rare, however. Concurrent RA may occur in about 3-67-2% of patients with SLE. 4 Cytotoxic drugs have had extensive use in RA and other CTD for both their direct therapeutic and steroid sparing effects.6 They are most commonly used singly, with or without concomitant corticosteroids, and usually administered daily. More recently, pulse therapy with cyclophosphamide has been used in both RA and SLE. 8 
